Patents by Inventor Katsue Inoue

Katsue Inoue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Function suppression type of genetically-modified rhodocytin mutant
    Patent number: 10208096
    Abstract: According to the present invention, a mutant rhodocytin lacking platelet aggregation ability is provided. According to the present invention, a pharmaceutical composition including a mutant rhodocytin lacking platelet aggregation ability is provided. According to the present invention, there is provided a method for inhibiting platelet aggregation by a platelet aggregating substance, including administering a pharmaceutical composition including a mutant rhodocytin lacking platelet aggregation ability to a subject in need thereof.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: February 19, 2019
    Assignee: University of Yamanashi
    Inventors: Tomoyuki Sasaki, Toshiaki Shirai, Katsue Inoue
  • FUNCTION SUPPRESSION TYPE OF GENETICALLY-MODIFIED RHODOCYTIN MUTANT
    Publication number: 20170320924
    Abstract: According to the present invention, a mutant rhodocytin lacking platelet aggregation ability is provided. According to the present invention, a pharmaceutical composition including a mutant rhodocytin lacking platelet aggregation ability is provided. According to the present invention, there is provided a method for inhibiting platelet aggregation by a platelet aggregating substance, including administering a pharmaceutical composition including a mutant rhodocytin lacking platelet aggregation ability to a subject in need thereof.
    Type: Application
    Filed: May 9, 2017
    Publication date: November 9, 2017
    Applicant: UNIVERSITY OF YAMANASHI
    Inventors: Tomoyuki SASAKI, Toshiaki SHIRAI, Katsue INOUE
  • Compositions and methods for treating hemostasis disorders associated with clec-2 signal transduction
    Publication number: 20090297508
    Abstract: The present invention provides a method for screening compounds to identify therapeutic candidates for treating hemostasis disorders, the method includes the steps of contacting a cell that expresses a CLEC-2 receptor with a test compound and a CLEC-2 receptor ligand, under conditions which, but for the presence of the test compound, permit binding of the CLEC-2 receptor to the CLEC-2 receptor ligand; and detecting if any increase or decrease in an indicator of CLEC-2 receptor activity is observed in comparison to a control; wherein an increase or decrease in the indicator in comparison to the control indicates that the test compound is a candidate for modulating hemostasis.
    Type: Application
    Filed: April 24, 2006
    Publication date: December 3, 2009
    Applicant: UNIVERSITY OF YAMANASHI
    Inventors: Yukio Ozaki, Katsue Inoue, Steve P. Watson